Studies holmium-166 radiation treatment for advanced liver cancer in past patients
Looks back at adults with advanced liver cancer treated with holmium-166 radioembolization.
Plain-language title generated from the registry record
Registry title: Holmium-166 Transarterial Radioembolization for the Treatment of Hepatocellular Carcinoma
Key facts
- Where
- Brussels, BelgiumSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with locally advanced liver cancer (hepatocellular carcinoma) that has not spread outside the liver and cannot be treated by surgery or ablation. It studies Holmium-166 radioembolization.
- Age
- 18 years or older
- Sex
- All sexes can join.
- Disease stage
- Locally advanced hepatocellular carcinoma without spread outside the liver. The cancer cannot be treated by surgical removal or percutaneous radiofrequency ablation. Liver function Child-Pugh A-B. ECOG performance status 0-2.
- Earlier treatment
- People cannot have had systemic therapy or radiation therapy to the liver for the liver cancer before.
- Biomarker or test result
- The tumor response must be measurable with mRECIST criteria during follow-up.
Main reasons for not taking part
- Earlier systemic therapy or liver radiation therapy for the liver cancer
- Metastatic disease
- Another cancer at the same time
- Currently in a study receiving an investigational drug
- Severe vascular disease or bleeding problems that rule out angiography, or severe uncontrolled illness with limited life expectancy
Read by machine on 12 November 2026.
Where in Belgium
- UZ BrusselBrussels, BelgiumContact: UZ BrusselTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Universitair Ziekenhuis Brussel
- Trial code
- NCT06873269
- Record updated
- 12 March 2025
- Original description
This study aims to evaluate the effectiveness and safety of Holmium-166 (Ho-166) transarterial radioembolization (TARE) for treating patients with locally advanced hepatocellular carcinoma (HCC), a common type of liver cancer. HCC is often linked to conditions like liver cirrhosis and viral hepatitis, with a poor prognosis for advanced stages. TARE involves delivering radioactive particles directly to liver tumors, sparing healthy tissue and providing targeted radiation.Read full original descriptionShow less
Holmium-166 Transarterial Radioembolization for the Treatment of Hepatocellular Carcinoma
This study aims to evaluate the effectiveness and safety of Holmium-166 (Ho-166) transarterial radioembolization (TARE) for treating patients with locally advanced hepatocellular carcinoma (HCC), a common type of liver cancer. HCC is often linked to conditions like liver cirrhosis and viral hepatitis, with a poor prognosis for advanced stages. TARE involves delivering radioactive particles directly to liver tumors, sparing healthy tissue and providing targeted radiation.
This study will include patients diagnosed with HCC who have received Holmium-166 TARE treatment between January 2010 and December 2024. Researchers will look at patient and tumor characteristics, side effects, how well the treatment works, and survival outcomes. The goal is to determine whether Holmium-166 TARE is a safe and effective treatment option for people with locally advanced HCC.
The findings will help doctors better understand how this therapy can be used to treat liver cancer and whether it can improve survival rates for patients with this challenging disease.
Inclusion: aged 18 year or older; diagnosed with locally advanced HCC without extra-hepatic metastases; HCC must not be amendable to treatment by surgical resection or percutaneous radiofrequency ablation; after assessment by the investigator and multidisciplinary tumor board, the patient is considered suitable for protocol treatment with Holmium-166 TARE; ECOG performance status 0-2; child-Pugh A-B; tumor response evaluable with mRECIST criteria during follow-up.
Exclusion: prior treatment with any of the following treatment modalities for HCC: systemic therapy, hepatic radiation therapy; currently enrolled in clinical studies where patient receive investigational therapeutic drug; concurrent malignancy; metastatic disease; active contra-indications to angiography or selective catherization (i.e. severe vascular disease or bleeding diathesis); uncontrolled and/or severe comorbidities (active infection, heart failure,...) with limited estimated life expectancy; history of or know allergic reactions to used compounds.